本周灵麦向您提供皮肤领域项目接洽服务
银屑病（即我们常说的牛皮癣）是一种常见的易于复发的慢性炎症性皮肤病，是多基因遗传背景下的自身免疫紊乱性疾病。自然人群的患病率为1%-2%。银屑病发生可从出生到90岁以上任何年龄，发病高峰在15-30岁。
根据EvaluatePharma预估医药数据库显示，全球银屑病市场预计到2022年达170亿美元，而目前国内轻中度银屑病患者主要用外用药物治疗，预计2019年外用药物市场份额可达10亿美元。LMP1014在北欧同类产品竞争中已有强劲表现，现授权伙伴已扩大到瑞士、意大利及德国等欧盟国家，而对更为庞大的亚洲市场存在更大的潜在销量。此外，LMP1014短期抢占欧洲市场的成功推广经验值得关注
LMP1014项目亮点
1. 银屑病全球市场将稳步增长，据华尔街金融界权威预测2022年将达170亿美金(EvaluatePharma)
2. 欧洲创新研发公司，专注皮肤疑难杂症
3. LMP1014产品在欧洲已上市3年，占据47%瑞典市场份额
4. LMP1014在中国并拥有配方专利，受专利保护
据灵麦分析团队初步接洽，该公司将于下周参加位于珠海的ChinaBio，心动就赶快行动，瑞典研发公司期待与您相见！如需项目对接，请联系我们 info@lingmed.net 或登录 www.lingmed.net/reports 下载报告全文
Do you want to have a “date” with Lingmed at ChinaBio?Partnering asset in Dermatological area
This week, Lingmed shares with you an partnering asset indermatological area
Psoriasis is a common, recurrent and chronic inflammatoryskin disease, a kind of autoimmune disease. The prevalence of naturalpopulation is 1% -2%. Psoriasis can occur from birth to 90 years old with peakincidence at 15-30 years old.
According to EvaluatePharma, the global psoriasis marketis expected to reach 17 billion US dollars at 2022. Currently, ChinesePsoriasis patients with mild to moderate symptoms are mainly treated withtopical drugs, which are expected to reach 1 billion US dollars in 2019. Facedwith fierce competition, LMP1014 shows excellent performance. Patent has beengranted for USA, Australia, Russia, China, Japan and NZ.
LMP1014 Project Highlights:
1. Steadyincreased Psoriasis market, which is expected to reach 17 billion US dollars byConsensus forecast (EvaluatePharma)
2. InnovativeEuropean biotech company, focused on skin disease
3. Have beenmarketed in European market for 3 years, occupying 47% market share
4. Thepatented formulation has been granted in China
After initial contact by Lingmed, The company willparticipate in ChinaBio Conference at Zhuhai next week.
For detailed information or free partnering support,please contact us at info@lingmed.net or visit www.lingmed.net/reports to download the full report.